Zervixkarzinomscreening

Für zahlreiche Diskussionen und Kontroversen hat in Deutschland die Einführung des organisierten Programms zur Früherkennung von Gebärmutterhalskrebs am 01. Januar 2020 gesorgt. Dieser Artikel stellt die durch das organisierte Screeningprogramm bedingten Neuerungen und deren Hintergründe dar und fasst die Empfehlungen der Arbeitsgemeinschaft für Zervixpathologie und Kolposkopie e. V. zum Vorgehen nach einer erfolgten Abklärungskolposkopie zusammen. Da auch Informationen zu HPV und HPV-Impfung für eine umfassende Aufklärung im Rahmen des Zervixkarzinomscreenings unerlässlich sind, werden auch hierzu aktuelle Daten präsentiert.

Schlüsselwörter

Zervixkarzinom - Dysplasie - Screening - humane Papillomaviren - Zytologie

• Literatur

• 1 IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Biological agents. Volume 100 B. A review of human carcinogens. IARC Monogr Eval Carcinog Risks Hum 2012; 100: 1-441
• 2 Walboomers JMM, Jacobs MV, Manos MM. et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999; 189: 12-19
• 3 Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF). Prävention des Zervixkarzinoms, Langversion 1.1. AWMF Registernummer: 015/027OL. 2020 Accessed October 10, 2022 at: http://www.leitlinienprogramm-onkologie.de/leitlinien/zervixkarzinom-praevention/
• 4 Schiffman M, Clifford G, Buonaguro FM. Classification of weakly carcinogenic human papillomavirus types: addressing the limits of epidemiology at the borderline. Infect Agent Cancer 2009; 4: 8
• 5 Cox JT, Schiffman M, Solomon D. Prospective follow-up suggests similar risk of subsequent cervical intraepithelial neoplasia grade 2 or 3 among women with cervical intraepithelial neoplasia grade 1 or negative colposcopy and directed biopsy. Am J Obstet Gynecol 2003; 188: 1406-1412
• 6 Doorbar J, Quint W, Banks L. et al. The biology and life-cycle of human papillomaviruses. Vaccine 2012; 30 (Suppl. 05) F55-F70
• 7 Schneider A, Hoyer H, Lotz B. et al. Screening for high-grade cervical intra-epithelial neoplasia and cancer by testing for high-risk HPV, routine cytology or colposcopy. Int J Cancer 2000; 89: 529-534
• 8 Petry KU, Menton S, Menton M. et al. Inclusion of HPV testing in routine cervical cancer screening for women above 29 years in Germany: results for 8466 patients. Br J Cancer 2003; 88: 1570-1577
• 9 Radde K, Gottschalk A, Bussas U. et al. Invitation to cervical cancer screening does increase participation in Germany: Results from the MARZY study. Int J Cancer 2016; 139: 1018-1030
• 10 Iftner T, Eberle S, Iftner A. et al. Prevalence of low-risk and high-risk types of human papillomavirus and other risk factors for HPV infection in Germany within different age groups in women up to 30 years of age: an epidemiological observational study. J Med Virol 2010; 82: 1928-1939
• 11 Wentzensen N, Rodriguez AC, Viscidi R. et al. A competitive serological assay shows naturally acquired immunity to human papillomavirus infections in the Guanacaste Natural History Study. J Infect Dis 2011; 204: 94-102
• 12 Schiffman M, Burk RD, Boyle S. et al. A study of genotyping for management of human papillomavirus-positive, cytology-negative cervical screening results. J Clin Microbiol 2015; 53: 52-59
• 13 Tjalma WA, Fiander A, Reich O. et al. Differences in human papillomavirus type distribution in high-grade cervical intraepithelial neoplasia and invasive cervical cancer in Europe. Int J Cancer 2013; 132: 854-867
• 14 Tainio K, Athanasiou A, Tikkinen KAO. et al. Clinical course of untreated cervical intraepithelial neoplasia grade 2 under active surveillance: systematic review and meta-analysis. BMJ 2018; 360: k499
• 15 Ostör AG. Natural history of cervical intraepithelial neoplasia: a critical review. Int J Gynecol Pathol 1993; 12: 186-192
• 16 McCredie MRE, Sharples KJ, Paul C. et al. Natural history of cervical neoplasia and risk of invasive cancer in women with cervical intraepithelial neoplasia 3: a retrospective cohort study. Lancet Oncol 2008; 9: 425-434
• 17 Becker N. Epidemiological aspects of cancer screening in Germany. J Cancer Res Clin Oncol 2003; 129: 691-702
• 18 Arbyn M, Anttila A, Jordan J. et al. European Guidelines for Quality Assurance in Cervical Cancer Screening. Second edition–summary document. Ann Oncol 2010; 21: 448-458
• 19 Gemeinsamer Bundesausschuss. Richtlinie des Gemeinsamen Bundesausschusses für Richtlinie des Gemeinsamen Bundesausschusses für organisierte Krebsfrüherkennungsprogramme. Accessed March 15, 2022 at: https://www.g-ba.de/downloads/62–492–2605/oKFE-RL-2021–07–01-iK-2022–01–01.pdf
• 20 Horn J, Denecke A, Luyten A. et al. Reduction of cervical cancer incidence within a primary HPV screening pilot project (WOLPHSCREEN) in Wolfsburg, Germany. Br J Cancer 2019; 120: 1015-1022
• 21 Khan MJ, Castle PE, Lorincz AT. et al. The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. J Natl Cancer Inst 2005; 97: 1072-1079
• 22 Peace SM, Jennings AJ. Prevalence of high-grade dysplasia in cytology-negative, HPV-positive cervical cancer screening. Arch Gynecol Obstet 2022; 305: 87-93
• 23 Arbeitsgemeinschaft für Zervixpathologie und Kolposkopie e. V.. Empfehlungen der AGCPC zum Vorgehen nach Abklärungskolposkopie und zur Nachsorge nach Exzisionen an der Zervix uteri. Accessed November 09, 2022 at: www.ag-cpc.de/wp-content/uploads/2021/12/Abklaerung-AGCPC-2021-Webseite.pdf
• 24 Hillemanns P. HPV-Screening in der Ko-Testung – Überforderung der Kolposkopie? 26. Jahrestagung der Arbeitsgemeinschaft für Zervixpathologie und Kolposkopie (AG CPC). 2021
• 25 Castellsagué X, Muñoz N, Pitisuttithum P. et al. End-of-study safety, immunogenicity, and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women 24–45 years of age. Br J Cancer 2011; 105: 28-37
• 26 Joura EA, Giuliano AR, Iversen OE. et al. A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. N Engl J Med 2015; 372: 711-723
• 27 Garland SM, Hernandez-Avila M, Wheeler CM. et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 2007; 356: 1928-1943
• 28 Wheeler CM, Castellsagué X, Garland SM. et al. Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol 2012; 13: 100-110
• 29 Robert Koch-Institut. Faktenblätter zum Impfen: HPV-Impfung. Accessed October 07, 2022 at: https://www.rki.de/DE/Content/Infekt/Impfen/Materialien/Faktenblaetter/HPV.pdf?__blob=publicationFile
• 30 Luostarinen T, Apter D, Dillner J. et al. Vaccination protects against invasive HPV-associated cancers. Int J Cancer 2018; 142: 2186-2187
• 31 Lei J, Ploner A, Elfström KM. et al. HPV vaccination and the risk of invasive cervical cancer. N Engl J Med 2020; 383: 1340-1348
• 32 Kjaer SK, Dehlendorff C, Belmonte F. et al. Real-world effectiveness of human papillomavirus vaccination against cervical cancer. J Natl Cancer Inst 2021; 113: 1329-1335